Tegafur/gimeracil/oteracil

No Colour

Brand Name(s):Teysuno

Indication:Advanced gastric cancer

Rationale:1,2,3

Considered:Jan-11

Review Date:45108

Comments:
PRAC Safety alert – Patients receiving iv or intraarterial fluorouracil, or capecitabine or tegafur (both prodrugs of FU), should be tested for lack of dihydropyrimidine dehydrogenase (DPD) before starting treatment – lack of DPD may lead to fluorouracil toxicity eg neutropenia, neurotoxicity.